Jacob Smith

30 Mar 2026

Novartis Deal Novartis is planning a $2 billion acquisition of biotec… – Jacob Smith

Novartis Deal Novartis is planning a $2 billion acquisition of biotech firm Excellergy, betting big on next-generation allergy treatments. The move underscores growing competition and innovation in the global pharmaceutical sector. #Novartis #Biotech #Pharma #Healthcare #Investment #Innovation